パーキンソン病治療薬の2030年までの世界市場

Report Highlights

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030.

Report Includes

• 46 data tables and 55 additional tables
• An overview of the global market for anti-Parkinson’s drugs
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, forecasts for 2030 and projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to anti-Parkinson’s drugs, accompanied by a market share analysis by drug class and region
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends in the market
• Insights derived from Porter’s Five Forces model, global value chain and case studies
• Patent analysis and emerging trends and developments in patent activity
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, M&As, joint ventures and other strategic alliances
• Descriptive profiles of leading companies, including AbbVie Inc., Amneal Pharmaceuticals LLC., Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals Inc., and Teva Pharmaceutical Industries Co. Ltd.

Report Scope

The report provides an overview of the global anti-Parkinson’s drugs market and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimated data for 2025 and forecast of compound annual growth rates (CAGRs) from 2025 to 2030. The market is segmented by drug class (based on mechanisms of action) and regions. By drug class, the market is segmented into dopaminergic, dopamine agonists, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase-B (MAO-B) inhibitors, anticholinergic and others. The regions covered in this study are North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, focusing on the major countries in these regions. The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea, Australia and the Rest of Asia-Pacific. The report focuses on the driving trends and challenges affecting the market. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report also includes an analysis of the competitive landscape and company profiles that address such details as overview, key financials, product portfolio and recent developments of key market businesses.

Executive Summary

Summary:

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030

Parkinson’s disease (PD) is a progressive neurodegenerative disease that frequently manifests as a lack of coordination, bradykinesia (slow movement), tremor, muscle rigidity and instability. More than 10 million people worldwide suffer from PD, the second most common age-related neurological illness. Pain, insomnia, psychosis, despair, anxiety, exhaustion and cognitive deterioration are examples of nonmotor symptoms, especially in individuals 40 years of age and older. Each PD symptom significantly impacts the patient’s quality of life (QOL). A significant increase in the elderly population has led to a sharp rise in the number of PD patients, which is now known as a Parkinson’s pandemic.

The drugs approved to treat the disease provide symptomatic relief, and no curative therapies have been approved. PD is marked by a high unmet need for disease-modifying therapies (DMT). Dopaminergic drugs (levodopa and carbidopa) are the gold standard of treatment. Other approved therapies include Inbrija (Merz Therapeutics), Duodopa (AbbVie), Ongentys (Amneal Pharmaceuticals/Bial), Xadago (Newron Pharmaceuticals) and Nuplazid (Acadia Pharmaceuticals), all of which aim to treat both motor and non-motor symptoms associated with the disease.

However, the current treatment landscape is evolving, with increased R&D activities focused on novel therapies. Several novel products have been approved in 2024 and 2025 that seek to address the limitations of the current therapies in use. These include FDA approval of Vyalev (foscarbidopa and foslevodopa) from AbbVie in October 2024 to treat motor fluctuations in adults with advanced PD. The drug is the first subcutaneous 24-hour infusion of levodopa-based therapy that provides enhanced efficacy compared to oral medications. In February 2025, the FDA approved a second drug-device combination product, Onapgo (apomorphine hydrochloride) from Supernus Pharmaceuticals, to treat motor fluctuations in adults with advanced PD.

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Emerging Technologies
Conclusion
Chapter 2 Market Overview
Overview and Market Definition
Pathophysiology
Symptoms
Diagnosis
Treatment and Management
Macroeconomic Factors Analysis
Demographic Factors
Environmental Factors
Geopolitical Factors
Economic Factors
Impact of U.S. Tariffs on the Anti-Parkinson’s Drugs Market
Porter’s Five Forces Analysis
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitute Products or Services (Moderate to High)
Industry Rivalry (High)
Supply Chain Analysis
Research and Development (R&D)
Manufacturing
Packaging
Wholesale Distributors and Repackagers
Pharmacies
Dispensed to Consumers
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Prevalence of Parkinson’s Disease
High Unmet Treatment Need Leads to Innovation
Industry Collaborations Accelerate R&D
Increased Public and Private Investments and Support
Market Restraints
Adverse Effects Associated with Anti-Parkinson’s Drugs
High Cost of Drug Development and Low Success Rate
Market Opportunities
Increased Awareness in Emerging Countries
Robust Pipeline
Chapter 4 Regulatory Landscape
Regulatory Aspects of Anti-Parkinson’s Drugs
United States
Europe
Japan
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Drug-Device Combinations
Cell and Gene Therapies
Vaccine
Monoclonal Antibodies
Other Combination Therapies
Pipeline Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Overview
Key Takeaways
Segmentation Breakdown
Market Analysis by Drug Class
Dopaminergic
Dopamine Agonists
Catechol-O-methyl Transferase Inhibitors
Monoamine Oxidase B Inhibitors
Anticholinergics
Others
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Key Takeaways
Market Share Analysis
Strategic Initiatives
Agreements, Collaborations and Partnerships
Acquisitions
Chapter 8 Sustainability in the Anti-Parkinson’s Drugs Global Market: An ESG Perspective
Introduction to ESG
Sustainability Trends and Initiatives
Environmental
Social and Governance Initiatives
ESG Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Research Methodology
Sources
Abbreviations
Company Profiles
ABBVIE INC.
ACADIA PHARMACEUTICALS INC.
AMNEAL PHARMACEUTICALS LLC.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
F. HOFFMANN-LA ROCHE LTD.
H. LUNDBECK A/S
KYOWA KIRIN CO. LTD.
MERZ THERAPEUTICS
NEUROCRINE BIOSCIENCES INC.
NEURODERM
NEWRON PHARMACEUTICALS SPA
NOVARTIS AG
PFIZER INC.
SUPERNUS PHARMACEUTICALS INC.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Start-ups/Market Disruptors

List of Tables

List of Tables
Summary Table : Global Market for Anti-Parkinson’s Drugs, by Region, Through 2030
Table 1 : NIH Funding Estimates for Parkinson’s Disease Research, 2019–2024
Table 2 : Selected List of Anti-Parkinson’s Drugs in Clinical Trials
Table 3 : Global Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 4 : Global Market for Dopaminergic Drugs, by Region, Through 2030
Table 5 : Classification of Dopamine Agonists
Table 6 : Global Market for Dopamine Agonist Drugs, by Region, Through 2030
Table 7 : Global Market for Catechol-O-Methyl Transferase (COMT) Inhibitor Drugs, by Region, Through 2030
Table 8 : Global Market for Monoamine Oxidase B (MAO-B) Inhibitor Drugs, by Region, Through 2030
Table 9 : Global Market for Anticholinergic Drugs, by Region, Through 2030
Table 10 : List of Other Common Drugs
Table 11 : Global Market for Other Anti-Parkinson’s Drugs, by Region, Through 2030
Table 12 : Global Market for Anti-Parkinson’s Drugs, by Region, Through 2030
Table 13 : North American Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 14 : North American Market for Anti-Parkinson’s Drugs, by Country, Through 2030
Table 15 : U.S. Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 16 : Canadian Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 17 : Mexican Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 18 : European Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 19 : European Market for Anti-Parkinson’s Drugs, by Country, Through 2030
Table 20 : German Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 21 : U.K Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 22 : French Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 23 : Spanish Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 24 : Italian Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 25 : Rest of Europe Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 26 : Asia-Pacific Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 27 : Asia-Pacific Market for Anti-Parkinson’s Drugs, by Country, Through 2030
Table 28 : Chinese Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 29 : Japanese Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 30 : Indian Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 31 : South Korean Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 32 : Australian Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 33 : Rest of Asia-Pacific Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 34 : RoW Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2030
Table 35 : RoW Market for Anti-Parkinson’s Drugs, by Country, Through 2030
Table 36 : Agreements, Collaborations and Partnerships in the Anti-Parkinson’s Drugs Market, 2021–2025
Table 37 : Acquisitions in the Anti-Parkinson’s Drugs Market, 2021–2024
Table 38 : Environmental Initiatives by Various Anti-Parkinson’s Drugs Manufacturers
Table 39 : Key Social and Governance Issues in Anti-Parkinson’s Drugs Market
Table 40 : ESG Risk Rankings for Anti-Parkinson’s Drugs Companies, 2024
Table 41 : Information Sources in this Report
Table 42 : Abbreviations Used in the Global Anti-Parkinson’s Drugs Market
Table 43 : AbbVie Inc.: Company Snapshot
Table 44 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 45 : AbbVie Inc.: Product Portfolio
Table 46 : AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 47 : Acadia Pharmaceuticals Inc.: Company Snapshot
Table 48 : Acadia Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 49 : Acadia Pharmaceuticals Inc.: Product Portfolio
Table 50 : Acadia Pharmaceuticals Inc.: News/Key Developments, 2022–2024
Table 51 : Amneal Pharmaceuticals LLC.: Company Snapshot
Table 52 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
Table 53 : Amneal Pharmaceuticals LLC.: Product Portfolio
Table 54 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2023 and 2024
Table 55 : Boehringer Ingelheim International GmbH: Company Snapshot
Table 56 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
Table 57 : Boehringer Ingelheim International GmbH: Product Portfolio
Table 58 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024 and 2025
Table 59 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 60 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 61 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 62 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
Table 63 : H. Lundbeck A/S: Company Snapshot
Table 64 : H. Lundbeck A/S: Financial Performance, FY 2023 and 2024
Table 65 : H. Lundbeck A/S: Product Portfolio
Table 66 : H. Lundbeck A/S: News/Key Developments, 2021–2024
Table 67 : Kyowa Kirin Co. Ltd.: Company Snapshot
Table 68 : Kyowa Kirin Co. Ltd.: Financial Performance, FY 2023 and 2024
Table 69 : Kyowa Kirin Co. Ltd.: Product Portfolio
Table 70 : Kyowa Kirin Co. Ltd.: News/Key Developments, 2022
Table 71 : Merz Therapeutics: Company Snapshot
Table 72 : Merz Therapeutics: Product Portfolio
Table 73 : Merz Therapeutics: News/Key Developments, 2024
Table 74 : Neurocrine Biosciences Inc.: Company Snapshot
Table 75 : Neurocrine Biosciences Inc.: Financial Performance, FY 2023 and 2024
Table 76 : Neurocrine Biosciences Inc.: Product Portfolio
Table 77 : Neurocrine Biosciences Inc.: News/Key Developments, 2023
Table 78 : NeuroDerm: Company Snapshot
Table 79 : NeuroDerm: Product Portfolio
Table 80 : NeuroDerm: News/Key Developments, 2024 and 2025
Table 81 : Newron Pharmaceuticals SpA: Company Snapshot
Table 82 : Newron Pharmaceuticals SpA: Financial Performance, FY 2023 and 2024
Table 83 : Newron Pharmaceuticals SpA: Product Portfolio
Table 84 : Newron Pharmaceuticals SpA: News/Key Developments, 2021
Table 85 : Novartis AG: Company Snapshot
Table 86 : Novartis AG: Financial Performance, FY 2023 and 2024
Table 87 : Novartis AG: Product Portfolio
Table 88 : Novartis AG: News/Key Developments, 2021–2024
Table 89 : Pfizer Inc.: Company Snapshot
Table 90 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 91 : Pfizer Inc.: Product Portfolio
Table 92 : Supernus Pharmaceuticals Inc.: Company Snapshot
Table 93 : Supernus Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 94 : Supernus Pharmaceuticals Inc.: Product Portfolio
Table 95 : Supernus Pharmaceuticals Inc.: News/Key Developments, 2021–2025
Table 96 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 97 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 98 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 99 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021
Table 100 : List of Few Emerging Startups in the Anti-Parkinson’s Drugs Market

List of Figures

List of Figures
Summary Figure : Global Market Shares of Anti-Parkinson’s Drugs, by Region, 2024
Figure 1 : Porter’s Five Forces Analysis of the Anti-Parkinson’s Drugs Market
Figure 2 : Supply Chain Process of Pharmaceutical Drugs
Figure 3 : Market Dynamics of Anti-Parkinson’s Drugs
Figure 4 : Clinical Trial Analysis, as of April 2025
Figure 5 : Number of Active PD Drug Trials, by Phase and Categories, 2024
Figure 6 : Global Market Shares of Anti-Parkinson’s Drugs, by Drug Class, 2024
Figure 7 : Global Market Shares of Anti-Parkinson’s Drugs, by Region, 2024
Figure 8 : North American Market Shares of Anti-Parkinson’s Drugs, by Country, 2024
Figure 9 : European Market Shares of Anti-Parkinson’s Drugs, by Country, 2024
Figure 10 : Asia-Pacific Market Shares of Anti-Parkinson’s Drugs, by Country, 2024
Figure 11 : Global Market Shares of Anti-Parkinson’s Drugs, by Key Companies, 2024
Figure 12 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 13 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 14 : Acadia Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 15 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
Figure 16 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit,FY 2024
Figure 17 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country,FY 2024
Figure 18 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 20 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2024
Figure 21 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2024
Figure 22 : Kyowa Kirin Co. Ltd.: Revenue Share by Country/Region, FY 2024
Figure 23 : Neurocrine Biosciences Inc.: Revenue Share, by Business Unit, FY 2024
Figure 24 : Newron Pharmaceuticals SpA: Revenue Share, by Business Unit, FY 2024
Figure 25 : Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 26 : Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 27 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 28 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 29 : Supernus Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
Figure 30 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Unit, 2024

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
• 免疫療法薬の世界市場 2025-11-12
• 農業におけるAIの世界市場 2025-11-10
• 世界の電気アーク炉市場 2025-11-07
• 固体酸化物形燃料電池の技術と世界市場 2025-11-07

BCC Research  出版レポート一覧